Anticardiolipin antibodies are not associated with restenosis or endothelial activation after percutaneous transluminal angioplasty

International Angiology

Volumn 16, Issue 2, 1997, Pages 88-93

  Tsakiris, D A ^a   Tschopl M ^a   Jager K ^a   Wolf, F ^a   Marbet, G A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Angioplasty, transluminal, percutaneous; Antibodies, anticardiolipin; Cell adhesion molecules; Endothelium, vascular

Indexed keywords

ANTITHROMBIN III; CARDIOLIPIN ANTIBODY; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; PADGEM PROTEIN; PROTHROMBIN; THROMBIN; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RESTENOSIS; TIME;

AGED; ANGIOPLASTY, BALLOON; ANTIBODIES, ANTICARDIOLIPIN; ARTERIAL OCCLUSIVE DISEASES; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PERIPHERAL VASCULAR DISEASES; PROSPECTIVE STUDIES; RECURRENCE; TIME FACTORS;

EID: 0030757348     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Beck AH, Muhe A, Ostheim W, Heiss W, Hasler K. Long term results of percutaneous transluminal angioplasty: a study of 4750 dilatations and local lyses. Eur J Vasc Surg 1989;3:245-52.
2. Morgenstern BR, Getraidman GJ, Laffey KJ, Bixon R, Martin EC. Total occlusions of the femoropopliteal artery: high technical success rate of conventional balloon angioplasty. Radiology 1989;172:937-40.
3. Matsi PJ, Manninen HJ, Vanninen RL, Suhonen MT, Oksala I, Hakkarainen T et al. Femoropopliteal angioplasty in patients with claudication: primary and secondary patency in 140 limbs with 1-3 year follow-up. Radiology 1994;19:727-33.
4. Haudenschild CC. Pathophysiology of reocclusion and restenosis. Fibrinolysis 1995;9(Suppl I):44-7.
5. O'Brien ER, Schwartz SM. Update on the biology and clinical study of restenosis. Trends Cardiovasc Med 1994;4:169-78.
6. Smith FB, Lowe GDO, Fowkes FGR, Rumley A, Rumley AG, Donnan PT et al. Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. Atherosclerosis 1993;102:155-62.
7. Blann AD, Dobrotova M, Kubisz P, McCollum. von Willebrand factor, soluble P-Selectin, Tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost 1995;74:626-30.
8. Triplett DA. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res 1995;78:1-31.
9. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and lupus anticoagulants in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990;112:682-98.
10. Triplett DA. Protean clinical presentation of antiphospholipid-protein antibodies (APA). Thromb Haemost 1995; 74:329-37.
11. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986;13:486-9.
12. Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome. J Rheumatol 1992;19:1778-81.
13. Levine SR, Brey RL, Sawaya KL et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995;38:119-24.
14. Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990;40:1990-6.
15. Hamsten A, Björkholm M, Norberg R, de Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986;1:113-6.
16. Vaarala O, Mänttäri M, Manninen V et al. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle aged men. Circulation 1995;91:23-7.
17. Raghavan C, Ditchfield J, Taylor RJ, Haeney MR, Barnes PC. Influence of anticardiolipin antibodies on immediate patient outcome after myocardial infarction. J Clin Pathol 1993;46:1113-5.
18. Tsakiris DA, Marbet GA, Burkart F, Duckert F. Anticardiolipin antibodies and coronary heart disease. Eur Heart J 1992;13:1645-8.
19. Lecerf V, Alhenc M, Laurian C et al. Antiphospholipid antibodies and atherosclerosis. Am J Med 1992;92:575-6.
20. Eber B, Schumacher M, Auer GP, Toplak H, Klein W. Increased IgM-anticardiolipin antibodies in patients with restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;69:1255-8.
21. Nityanand S, Bergmark C, de Faire U, Swedenborg J, Holm G, Lefvert AK. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med 1995;238: 437-43.
22. Bacharach JM, Lie JT, Homburger HA. The prevalence of vascular occlusive disease associated with antiphospholipid syndromes. Int Angiol 1992;11:51-6.
23. McGee GS, Pearce WH, Sharma L, Green D, Yao JS. Antiphospholipid antibodies and arterial thrombosis. Case reports and a review of the literature. Arch Surg 1992;127:342-6.
24. Nitecki S, Brenner B, Hoffman A, Lanir N, Schramek A, Torem S. Lower limb ischemia in primary antiphospholipid syndrome. Eur I Vasc Surg 1993;7:414-9.
25. Ross R. The pathogenesis of atherosclerosis, a perspective for the 1990s. Nature 1993;362:801-9.
26. Jäger KA, Phillips DJ, Martin RL, Hanson C, Roederer GO, Langlois YE et al. Noninvasive mapping of lower limb arterial lesions. Ultrasound Med Biol. 1985; 11:515-21.
27. Labs KH, Fitzgerald DE. Quantification of pulsed Doppler spectra for the diagnosis of minor to moderate atherosclerotic lesions: experience from in vitro and in vivo models. In: Labs KH, Jäger KA, Fitzgerald DE, Woodcock JP, Neuerburg-Heusler D, editors. Diagnostic vascular ultrasound. London: Edward Arnold, 1992:126-42.
28. Grüntzig A, Hopff H. Perkutane Rekanalisation chronischer arterieller Verschlüsse mit einem neuen Dilatationskatheter. Dtsch Med Wschr 1974;99:2502-5.
29. Eldrup-Jorgensen J, Brace L, Flanigan DR et al. Lupuslike anticoagulants and lower extremity arterial occlusive disease. Circulation 1989;80(5Pt2):III54-8.
30. Fields RA, Toubbeh H, Searles RP, Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989;16:623-5.
31. Sletnes KE, Larsen EW, Stokland O. Wisloff F. Antiphospholipid antibodies detected as anticephalin and anticardiolipin antibodies in patients with acute myocardial infarction: immunological response to myocardial necrosis? Thromb Res 1990;59:675-80.
32. Anglin P, Strauss BH, Brandwein JM, Watson KR. Lupus anticoagulant: a potential risk factor for complication following percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn 1994;31:130-2.
33. Anonymous editorial. Atherosclerosis goes to the wall. Lancet 1992;339:647-8.
34. Alarcon-Segovia D, Cardiel MH, Reyes E. Antiphospholipid arterial vasculopathy. J Rheumatol 1989; 16:762-7.
35. Seigneur M, Dufourq P, Conri C, Constans J, Mercie P, Pruvost A, Boisseau M. Plasma thrombomodulin: new approach of endothelial damage. Int Angiol 1993; 12:355-9.
36. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993,14:506-12.
37. Bevilacqua MP, Nelson RM. Selectins. I Clin Invest 1993;91:379-87.